Skip to main content

Table 5 Current mTOR inhibitor and immune therapy trials for MIBC*

From: Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review

Institution Regimen Setting Trial description Status Trial ID
UTHSCSA Sirolimus Neoadjuvant Phase 0 trial for preoperative treatment. Tissue evaluated before and after treatment. Recruiting NCT01827618
Hoosier oncology group Everolimus +/− Paclitaxel Unspecified^ Phase II trial for Cisplatin ineligible patients. Not a perioperative specific study. Recruiting NCT01215136
University of Washington Sirolimus + GC Unspecified^ Phase I/II trial for disease of any stage. Patients likely will undergo cystectomy. Ongoing NCT01938573
MDACC INF-alpha Prior to Biopsy Phase 1 trial with TURBT conducted following treatment. Radical cystectomy may follow. Ongoing NCT00082719
  1. GC = Gemcitabine + Cisplatin. UTHSCSA = The University of Texas Health Science Center at San Antonio. MDACC = M.D. Anderson Cancer Center. TURBT = Transurethral Resection of Bladder Tumor.
  2. *Table does not include trials for multiple solid tumors that may include bladder cancer as a subset.
  3. ^Unspecified regimens can be given in the neoadjuvant, adjuvant, locally recurrent, or metastatic setting.